Dr Connor Blair

  • Research Fellow (Cardiovascular & Metabolic Health)

Biography

  • BSc (Hons) Neuroscience
  • MRes in Biomedical Sciences
  • PhD  Molecular Pharmacology

Research interests

Discovering and developing highly-selective peptide modulators of pathological protein-protein interactions as novel therapeutics in Oncology.

  • Peptide-based therapeutics
  • Cell-penetrating peptides
  • Protein-Protein Interactions
  • Pharmacology
  • Cell Biology

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019
Number of items: 13.

2024

Sin, Y. Y. et al. (2024) Beta-amyloid interacts with and activates the longform phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability. FEBS Letters, (doi: 10.1002/1873-3468.14902) (PMID:38724485) (Early Online Publication)

Cooke, S. F. et al. (2024) Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC. Scientific Reports, 14, 8998. (doi: 10.1038/s41598-024-59451-3) (PMID:38637546)

Cooke, S. F. and Blair, C. M. (2024) Exploiting c-RAF dependency in RAS mutant cancer: Beyond catalytic activity. Expert Review of Anticancer Therapy, 24(3-4), pp. 95-100. (doi: 10.1080/14737140.2024.2319035)

2023

Brown, A. D., Vergunst, K. L., Branch, M., Blair, C. M., Dupré, D. J., Baillie, G. S. and Langelaan, D. N. (2023) Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor. Biochimica et Biophysica Acta: Molecular Cell Research, 1870(7), 119520. (doi: 10.1016/j.bbamcr.2023.119520) (PMID:37353163)

Wright, T. A., Gemmell, A. O., Tejeda, G. S. , Blair, C. M. and Baillie, G. S. (2023) Cancer: phosphodiesterase type 4C (PDE4C), the forgotten subfamily as a therapeutic target. International Journal of Biochemistry and Cell Biology, 162, 106453. (doi: 10.1016/j.biocel.2023.106453) (PMID:37499270)

Paes, D. et al. (2023) Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology. Cellular and Molecular Life Sciences, 80(7), 178. (doi: 10.1007/s00018-023-04804-w) (PMID:37306762) (PMCID:PMC10261250)

2022

Tibbo, A. J. et al. (2022) Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. Journal of Molecular and Cellular Cardiology, 165, pp. 86-102. (doi: 10.1016/j.yjmcc.2022.01.001) (PMID:34999055) (PMCID:PMC8986152)

2021

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

2020

Ling, J., Blair, C. M. and Baillie, G. S. (2020) Fibrin Breakdown Assay. Bio-Protocol, 10(8), e3585. (doi: 10.21769/BioProtoc.3585)

Blair, C. M., Ling, J. and Baillie, G. S. (2020) Measuring cAMP specific phosphodiesterase activity: a two-step radioassay. Bio-Protocol, 10(7), e3581. (doi: 10.21769/BioProtoc.3581) (PMID:33659551) (PMCID:PMC7842805)

2019

Blair, C. M. and Baillie, G. S. (2019) Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 47(5), pp. 1405-1414. (doi: 10.1042/BST20190252) (PMID:31506329)

Blair, C. M., Walsh, N., Littman, B. H., Marcoux, F. W. and Baillie, G. S. (2019) Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf. BMC Cancer, 19, 266. (doi: 10.1186/s12885-019-5489-4) (PMID:30909892) (PMCID:PMC6434832)

This list was generated on Sun Jul 21 01:11:10 2024 BST.
Jump to: Articles
Number of items: 13.

Articles

Sin, Y. Y. et al. (2024) Beta-amyloid interacts with and activates the longform phosphodiesterase PDE4D5 in neuronal cells to reduce cAMP availability. FEBS Letters, (doi: 10.1002/1873-3468.14902) (PMID:38724485) (Early Online Publication)

Cooke, S. F. et al. (2024) Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC. Scientific Reports, 14, 8998. (doi: 10.1038/s41598-024-59451-3) (PMID:38637546)

Cooke, S. F. and Blair, C. M. (2024) Exploiting c-RAF dependency in RAS mutant cancer: Beyond catalytic activity. Expert Review of Anticancer Therapy, 24(3-4), pp. 95-100. (doi: 10.1080/14737140.2024.2319035)

Brown, A. D., Vergunst, K. L., Branch, M., Blair, C. M., Dupré, D. J., Baillie, G. S. and Langelaan, D. N. (2023) Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor. Biochimica et Biophysica Acta: Molecular Cell Research, 1870(7), 119520. (doi: 10.1016/j.bbamcr.2023.119520) (PMID:37353163)

Wright, T. A., Gemmell, A. O., Tejeda, G. S. , Blair, C. M. and Baillie, G. S. (2023) Cancer: phosphodiesterase type 4C (PDE4C), the forgotten subfamily as a therapeutic target. International Journal of Biochemistry and Cell Biology, 162, 106453. (doi: 10.1016/j.biocel.2023.106453) (PMID:37499270)

Paes, D. et al. (2023) Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology. Cellular and Molecular Life Sciences, 80(7), 178. (doi: 10.1007/s00018-023-04804-w) (PMID:37306762) (PMCID:PMC10261250)

Tibbo, A. J. et al. (2022) Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins. Journal of Molecular and Cellular Cardiology, 165, pp. 86-102. (doi: 10.1016/j.yjmcc.2022.01.001) (PMID:34999055) (PMCID:PMC8986152)

Mahindra, A. et al. (2021) Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE, 16(11), e0260283. (doi: 10.1371/journal.pone.0260283) (PMID:34793553) (PMCID:PMC8601423)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Ling, J., Blair, C. M. and Baillie, G. S. (2020) Fibrin Breakdown Assay. Bio-Protocol, 10(8), e3585. (doi: 10.21769/BioProtoc.3585)

Blair, C. M., Ling, J. and Baillie, G. S. (2020) Measuring cAMP specific phosphodiesterase activity: a two-step radioassay. Bio-Protocol, 10(7), e3581. (doi: 10.21769/BioProtoc.3581) (PMID:33659551) (PMCID:PMC7842805)

Blair, C. M. and Baillie, G. S. (2019) Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. Biochemical Society Transactions, 47(5), pp. 1405-1414. (doi: 10.1042/BST20190252) (PMID:31506329)

Blair, C. M., Walsh, N., Littman, B. H., Marcoux, F. W. and Baillie, G. S. (2019) Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf. BMC Cancer, 19, 266. (doi: 10.1186/s12885-019-5489-4) (PMID:30909892) (PMCID:PMC6434832)

This list was generated on Sun Jul 21 01:11:10 2024 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • DRx-992 against TP53 mutant Neuroblastoma
    Medical Research Council
    2024 - 2025
     
  • Optimisation of c-RAF inhibitor peptide for KRAS-driven pancreatic cancer
    Medical Research Council
    2023 - 2024
     
  • Lead optimisation of an allosteric c-RAF inhibitor peptide for the treatment of KRAS-driven pancreatic cancer
    Engineering and Physical Sciences Research Council
    2023 - 2024
     
  • Peptide Therapeutics Spin-Out Programme Grant
    Scottish Enterprise
    2023 - 2024
     
  • Inhibiting c-Raf activity and treating pancreatic cancer
    Medical Research Council
    2022 - 2022
     
  • Inhibiting c-Raf activity and treating pancreatic cancer - Follow on
    Medical Research Council
    2022 - 2023